Published in AIDS on October 18, 2007
Occult HBV infection. Semin Immunopathol (2012) 1.37
Occult hepatitis B virus infection: A major concern in HIV-infected patients: Occult HBV in HIV. Hepat Mon (2011) 0.95
Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol (2014) 0.85
Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med (2008) 13.35
PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol (2006) 5.46
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology (2007) 3.73
Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol (2008) 3.50
Care of patients with hepatitis C and HIV co-infection. AIDS (2004) 3.46
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology (2004) 2.87
Occult hepatitis B virus infection. J Hepatol (2006) 2.79
Mitigation measures for pandemic influenza in Italy: an individual based model considering different scenarios. PLoS One (2008) 2.54
Control of cccDNA function in hepatitis B virus infection. J Hepatol (2009) 2.41
Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol (2002) 2.26
Resurgence of pertussis in Europe. Pediatr Infect Dis J (2005) 2.23
Variation in genes encoding for interferon λ-3 and λ-4 in the prediction of HCV-1 treatment-induced viral clearance. Liver Int (2013) 2.07
gp120 modulates the biology of human hepatic stellate cells: a link between HIV infection and liver fibrogenesis. Gut (2009) 2.06
Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. J Hepatol (2013) 2.04
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS (2007) 2.00
Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology (2012) 1.92
IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome. J Clin Invest (2012) 1.81
Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology (2006) 1.81
Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A (2009) 1.74
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS (2005) 1.71
High HIV prevalence in male patients with acute hepatitis A in the Rome metropolitan area, Italy 2002-2008. J Hepatol (2011) 1.71
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology (2011) 1.70
Complex traditional Chinese medicine for poststroke motor dysfunction: a systematic review. Stroke (2009) 1.69
HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. J Hepatol (2012) 1.69
Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology (2009) 1.65
Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol (2002) 1.62
Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol (2005) 1.58
Assessment of measles incidence, measles-related complications and hospitalisations during an outbreak in a southern Italian region. Vaccine (2005) 1.55
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology (2004) 1.52
The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver Int (2010) 1.51
Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J Hepatol (2013) 1.50
African sleeping sickness in tourists returning from Tanzania: the first 2 Italian cases from a small outbreak among European travelers. Clin Infect Dis (2001) 1.49
Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS (2007) 1.48
The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology (2008) 1.42
Occult HBV infection. Semin Immunopathol (2012) 1.37
Plasmacytoid dendritic cells in acute and chronic hepatitis C virus infection. Hepatology (2005) 1.33
Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer (2006) 1.33
Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol (2008) 1.31
Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology (2007) 1.31
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS (2002) 1.30
Atherosclerosis is associated with multiple pathogenic mechanisms in HIV-infected antiretroviral-naive or treated individuals. AIDS (2013) 1.29
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. J Hepatol (2010) 1.27
Gender differences in antiretroviral drug-related adipose tissue alterations. Women are at higher risk than men and develop particular lipodystrophy patterns. J Acquir Immune Defic Syndr (2003) 1.25
Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology (2009) 1.24
Huangqi injection (a traditional Chinese patent medicine) for chronic heart failure: a systematic review. PLoS One (2011) 1.23
European Guidelines for Control and Prevention of Travel Associated Legionnaires' Disease: the Italian experience. Euro Surveill (2004) 1.18
Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection. PLoS One (2007) 1.16
Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. Vaccine (2007) 1.14
Clinical, social and relational determinants of paediatric ambulatory drug prescriptions due to respiratory tract infections in Italy. Eur J Clin Pharmacol (2006) 1.14
The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver. Oncogene (2002) 1.13
Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis. Clin J Am Soc Nephrol (2010) 1.12
Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection. J Hepatol (2002) 1.10
Use of whole-blood samples in in-house bulk and single-cell antigen-specific gamma interferon assays for surveillance of Mycobacterium tuberculosis infections. Clin Vaccine Immunol (2007) 1.09
Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol (2011) 1.08
HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin. J Hepatol (2004) 1.08
Transglutaminase type II plays a protective role in hepatic injury. Am J Pathol (2003) 1.06
Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis (2011) 1.03
Incidence of vaccine preventable pneumococcal invasive infections and blood culture practices in Italy. Vaccine (2005) 1.03
Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med (2002) 1.03
Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis (2013) 1.02
Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) database. J Antimicrob Chemother (2013) 1.02
What is the clinical impact of occult hepatitis B virus infection? Lancet (2005) 1.01
Health burden and economic impact of measles-related hospitalizations in Italy in 2002-2003. BMC Public Health (2007) 1.01
Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J Virol (2010) 1.01
Tuberculoid leprosy in a patient with AIDS: a manifestation of immune restoration syndrome. Scand J Infect Dis (2004) 1.00
Mutations in the dihydropteroate synthase gene of human-derived Pneumocystis carinii isolates from Italy are infrequent but correlate with prior sulfa prophylaxis. J Infect Dis (2002) 0.99
Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection. Gut (2012) 0.98
Measles serological survey in the Italian population: interpretation of results using mixture model. Vaccine (2008) 0.97
Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study. J Acquir Immune Defic Syndr (2003) 0.95
A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther (2009) 0.94
Non-sequencing molecular approaches to identify preS2-defective hepatitis B virus variants proved to be associated with severe liver diseases. J Hepatol (2004) 0.94
Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J Peripher Nerv Syst (2006) 0.93
How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy. Vaccine (2005) 0.93
Comparison of pertussis surveillance systems in Europe. Vaccine (2006) 0.92
Interferon may prevent HIV viral rebound after HAART interruption in HIV patients. J Interferon Cytokine Res (2008) 0.91
Genotyping of Pneumocystis jiroveci pneumonia in Italian AIDS patients. Clinical outcome is influenced by dihydropteroate synthase and not by internal transcribed spacer genotype. J Acquir Immune Defic Syndr (2007) 0.90
Targeting hepatitis B virus-infected cells with a T-cell receptor-like antibody. J Virol (2010) 0.90
The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis. J Gastroenterol (2012) 0.90
Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations. Antivir Ther (2003) 0.90
Conserved transactivating and pro-apoptotic functions of hepadnaviral X protein in ortho- and avihepadnaviruses. Oncogene (2002) 0.88
Different evolutionary rates and epidemic growth of hepatitis B virus genotypes A and D. Virology (2008) 0.88
Accumulation of dysfunctional effector CD8+ T cells in the liver of patients with chronic HCV infection. J Hepatol (2005) 0.88
Hepatitis B vaccination. Hum Vaccin Immunother (2014) 0.88